Format

Send to

Choose Destination
Cancer Genomics Proteomics. 2019 Sep-Oct;16(5):345-351. doi: 10.21873/cgp.20139.

Fusion of the Genes PHF1 and TFE3 in Malignant Chondroid Syringoma.

Author information

1
Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway ioannis.panagopoulos@rr-research.no.
2
Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
3
Department of Pathology, Oslo University Hospital, Oslo, Norway.
4
Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.

Abstract

BACKGROUND/AIM:

Malignant chondroid syringoma is a rare tumor of unknown pathogenesis.

MATERIALS AND METHODS:

Genetic analyses were performed on a malignant chondroid syringoma.

RESULTS:

G-banding analysis of short-term cultured tumor cells yielded the karyotype 46,Y,t(X;6)(p11;p21)[15]/46,XY[2]. RNA sequencing detected an in-frame fusion of PHF1 from 6p21 with TFE3 from Xp11, verified by RT-PCR and Sanger sequencing. Genomic PCR showed that the PHF1-TFE3 junction was identical to the fusion found by RNA sequencing and RT-PCR.

CONCLUSION:

Malignant chondroid syringoma is genetically related to tumors with PHF1 rearrangements such as low-grade endometrial sarcoma and ossifying fibromyxoid tumor, but also with tumors having TFE3 rearrangements such as renal cell carcinoma, alveolar soft part sarcoma, PEComa, and epithelioid hemangioendothelioma. Further investigations on malignant chondroid syringomas are needed in order to determine whether genetic heterogeneity exists among them and the clinical impact of the PHF1-TFE3 fusion.

KEYWORDS:

Malignant chondroid syringoma; PHF1; PHF1-TFE3 fusion gene; RNA sequencing; TFE3

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center